FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
